Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model

American Journal of Hematology

Volumn 76, Issue 4, 2004, Pages 398-404

  Chan, Godfrey Chi Fung ^a   Ng, D M W ^a   Fong, D Y T ^a   Ha, S Y ^a   Lau, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Iron chelation therapy; Subcutaneous needle; Thalassemia

Indexed keywords

DEFEROXAMINE MESYLATE;

ADULT; ARTICLE; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; EDEMA; FEMALE; HUMAN; INJECTION PAIN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; NEEDLE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; STATISTICAL ANALYSIS; THALASET NEEDLE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; CHELATION THERAPY; CHILD; CROSS-OVER STUDIES; DEFEROXAMINE; EDEMA; EQUIPMENT DESIGN; ERYTHEMA; FEMALE; HUMANS; INFUSIONS, PARENTERAL; IRON CHELATING AGENTS; MALE; MIDDLE AGED; NEEDLES; PAIN; PRURITUS; QUESTIONNAIRES; SUBCUTANEOUS TISSUE; THALASSEMIA;

EID: 3343015551     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20103     Document Type: Article

References (17)

1. Rebulla P. Blood transfusion in beta thalassaemia major. Transfus Med 1995;5:247-258.
2. Porter JB. A risk benefit assessment of iron chelation therapy. Drug Saf 1997;17:407-421.
3. Hoffbrand AV, Wonke B. Iron chelation therapy. J Intern Med Suppl 1997;740:37-41.
4. Oliver D. The tonicity of solutions used in continuous subcutaneous infusions. Hosp Pharm Pract 1991;1(4):158-164.
5. Dawkins L, Britton D, Johnson I, Higgins B, Dean T. A randomized trial of winged Vialon cannula and metal butterfly needles. Int J Palliat Nurs 2000;6(3):110-116.
6. Currow D, Cooney N. Comparison of metal versus Vialon subcutaneous catheters in a palliative care setting. Palliat Med 1994;8:333-336.
7. Fetzer SJ. Reducing venipuncture and intravenous insertion pain with eutectic mixture of local anesthetic: a meta-analysis. Nurs Res 2002;51(2):119-124.
8. Caro J, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Blood Disord 2002;2(1):4.
9. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002;360(9332):516-520.
10. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator dereriprone: a multicentre study. Br J Haematol 2000;108(2):305-312.
11. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. BrJ Haematol 1998;101(3):413-415.
12. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332(14):918-922.
13. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol 2002;76(3):219-228.
14. Arboretti R, Tognoni G, Alberti D, Italian Collaborative Group on Thalassaemia. Pharmacosurveillance and quality of care of thalassaemic patients. A large-scale epidemiological survey. Eur J Clin Pharmacol 2001;56(12):915-922.
15. Goodenough B, Kampel L, Champion GD, et al. An investigation of the placebo effect and age-related factors in the report of needle pain from venipuncture in children. Pain 1997;72(3): 383-391.
16. Hadjistavropoulos T, Craig KD. A theoretical framework for understanding self-report and observational measures of pain: a communications model. Behav Res Ther 2002;40(5):551-570.
17. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20(4):246-252.